Medtech Accelerator Sofinnova MD Start III Launches a Call for Early Stage Medical Device Projects
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its medtech accelerator, Sofinnova MD Start III, is launching a call for early-stage projects. Sofinnova MD Start III is part of the Sofinnova platform of funds and actively works with clinicians and entrepreneurs to develop disruptive therapeutic medical devices. This call for projects aims to award funding and mentorship to selected projects through the MDS III accelerator program. Proposals will be accepted until July 9th, 2021 via the online application form.
The Sofinnova MD Start III Fund recently raised over €50 million from key institutional and corporate investors and is managed by a dedicated team of serial entrepreneurs and clinicians. The fund’s goal is to transform innovative ideas into medical realities by creating and building world-class medical device companies dedicated to the development of novel therapeutic medical devices and procedures. To date, the fund has created 10 companies and reviewed over 2000 projects.
Sofinnova MD Start III has privileged access to breakthrough technologies in healthcare through its network of scientists and experts from the top research and development centers around the world. This call for proposals aims to build on the fund’s existing deal flow to enable greater access to funding and support to promising early-stage projects or companies with a strong clinical impact and a high potential to improve patient lives.
Selected projects will receive financial contribution through a maturation grant or an investment from the Sofinnova MD Start III Fund, as well as operational support, in line with the model of the accelerator as a hands-on, joint project development with inventors.
Anne Osdoit, Partner at Sofinnova Partners and a key member of the Sofinnova MD Start III Fund team, said “We are looking for the most promising cutting edge therapeutic projects in the medical device sector. With our strong operational, financial and strategic expertise as well as our vast industry network, we are able to provide the key components to successfully build companies that will advance patient care and medtech innovation.”
The review and selection process will be conducted by the Sofinnova MD Start III team, which consists of medical, scientific and engineering professionals, with extensive experience in medtech entrepreneurship and a strong network of stakeholders across the industry, corporate partners, and investors.
Sofinnova MD Start III builds on the success of MD Start I and MD Start II in creating and accelerating companies that offer revolutionary solutions for unmet medical needs, bridging the gap between patient care and medical device innovation.
###
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005876/en/
Contact information
Media:
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneyco.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Rafaella Casula
rafaella.casula@havaspr.com
+39 (0) 345 3780834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Adds Dynamic Rate Management for EI Residential Solar-Plus-Storage Solution in EU9.12.2025 06:00:00 EET | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced the addition of Dynamic Rate Management to the Tigo EI Residential solar-plus-storage solution. This new capability enables Tigo all-in-one ecosystem to intelligently respond dynamically to changes in electricity rates. This addition of Dynamic Rate Management comes at a time when European energy companies are rapidly expanding the use of dynamic rates across several EU nations. The Dynamic Rate Manager will be available for new Tigo EI customers as well as existing EI Residential system owners as a part of a software update with no additional hardware, accessories, or configuration required. The Dynamic Rate Management feature allows the EI Residential solution to automatically acquire and interpret wholesale dynamic energy prices, often updated on a day-ahead basis, and plan system behaviour to optimize the use of solar, battery, and grid powe
SII Begins Mass Production of the World’s Smallest (1.0 × 0.8 × 0.32mm) Tuning-Fork Crystal Resonator “SC-10S”9.12.2025 04:00:00 EET | Press release
Seiko Instruments Inc. (President: Yoichi Endo; Headquarters: Chiba City, Chiba Prefecture; hereinafter “SII”) will begin mass production of the “SC-10S” (32.768kHz), the world’s smallest* tuning-fork crystal resonator measuring 1.0 × 0.8mm, starting in April 2026. *Based on SII research as of November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202800779/en/ Product Image-1 [Background of Development] SII has already been mass-producing the “SC-12S” (32.768kHz), one of the world’s smallest tuning-fork crystal resonators at 1.2 × 1.0mm. As wearable devices such as smart rings and smartwatches, as well as IoT devices, continue to become smaller, the electronic components built into these devices are increasingly required to support high-density mounting, low power consumption, and high performance. To meet these needs, SII leveraged its proprietary photolithography technology to develop and mass-produce the world’
Verimatrix: Signing of an Agreement for the Sale of XTD Assets (Code and Application Protection) to Guardsquare8.12.2025 18:45:00 EET | Press release
Regulatory News: VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of user security solutions for a safer connected world, announces the signing of an agreement with Belgium-based Guardsquare, the leading provider of mobile application security, for the sale of its Extended Threat Defense (XTD) assets. Guardsquare, the creators of the open-source optimization tool, ProGuard, offers the most complete mobile application security platform on the market spanning automated testing and multi-layered protection, real time threat monitoring, and app attestation. Guardsquare’s 975+ customers are located in more than 95 countries and represent all major industries. Launched in 2021, Verimatrix's Extended Threat Defence (XTD) business is composed of a group of cybersecurity experts specialised in protecting mobile, web and desktop applications. Using a range of innovative solutions, XTD solutions predict, detect and respond to threats before their targets are compromised. Over th
WNBA Champion Sabrina Ionescu Becomes Global Brand Ambassador for Ant International8.12.2025 18:00:00 EET | Press release
Four-time WNBA All-Star Sabrina Ionescu today becomes a new Global Brand Ambassador for Ant International, a leading global provider of digital payments, digitisation, and financial technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208536426/en/ The partnership is built on a shared commitment to creating a more inclusive and sustainable world through empowering underserved communities and youth groups with sports and technology innovation. It marks an important step in Ant International’s journey to foster growth and expand access to financial tools through innovative technology. Ionescu serves as the first Ant International global brand ambassador from North America. “Sabrina embodies the spirit of perseverance and the passion for excellence that is driving young talents and small businesses around the world to uplift their communities,” said Douglas Feagin, President of Ant International. “As a legend in a spor
SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer8.12.2025 17:20:00 EET | Press release
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2025, held December 9–12 in San Antonio, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208979141/en/ These abstracts showcase the growing clinical utility and innovation of the company’s proprietary RNA platform and underscore REVEAL GENOMICS’ commitment to improving outcomes for individuals with breast cancer. Across all studies, REVEAL GENOMICS and its collaborators analyzed more than 1,300 tumor samples from individuals with HER2-positive, ER-negative, and triple-negative breast cancer—one of the most extensive genomic contributions to SABCS 2025. Seven independent studies validate the performance and clinical impact of REVEAL GENOMICS’ precision oncology platform New HER2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom